FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
Transition Therapeutics Inc. announced that the United States food and Drug Administration has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. for the treatment of Alzheimer's disease.
AZD-103/ELND005 is currently being evaluated in multiple Phase I clinical studies, and the companies anticipate starting Phase II clinical studies around the end of 2007.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Commonwealth Scientific and Industrial Research Organisation (CSIRO) - Canberra, Australia
NiKem Research Srl and Dualsystems Biotech AG Announce a Strategic Alliance
Drug discovery potential of natural microbial genomes - Advanced genetic technique yields novel antibiotic from ocean bacteria
Genmab licenses agiogenesis targets from Bionomics

Training bees to smell the coronavirus - A trained bee can detect an infected sample within a few seconds
